<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02194127</url>
  </required_header>
  <id_info>
    <org_study_id>1147.2</org_study_id>
    <nct_id>NCT02194127</nct_id>
  </id_info>
  <brief_title>Efficacy and Tolerability of a Bilberry Extract in Volunteers With Impaired Twilight and Night Vision</brief_title>
  <official_title>Efficacy and Tolerability of a Treatment Over 28 Days With a Bilberry Extract Standardised to a Content of 25% Anthocyanidines in Volunteers With Impaired Twilight and Night Vision</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      Study to determine the efficacy of Anthocyan to improve impaired twilight and night vision
      and to test its tolerability and safety.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 1998</start_date>
  <primary_completion_date type="Actual">June 1999</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Measurement of the maximum velocity of dilatation of the pupil</measure>
    <time_frame>day 29</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Measurement of the maximum velocity of dilatation of the pupil</measure>
    <time_frame>Days 1 and 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of the initial pupil diameter</measure>
    <time_frame>days 1, 8 and 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of the latency time</measure>
    <time_frame>Days 1, 8 and 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of the absolute and relative constriction amplitude</measure>
    <time_frame>Days 1, 8 and 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of maximum velocity of contraction</measure>
    <time_frame>Days 1, 8 and 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of velocity of contraction 2</measure>
    <time_frame>Days 1, 8 and 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of initial minimal contrast level</measure>
    <time_frame>Days 1, 8 and 29</time_frame>
    <description>Determined with Gecko Contrast card</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to regain contrast vision at one level above the initial minimal contrast</measure>
    <time_frame>days 1, 8 and 29</time_frame>
    <description>Determined with Gecko Contrast card</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of contrast threshold level at illumination 0.1 cd/m2 with glare</measure>
    <time_frame>Days 1, 8 and 29</time_frame>
    <description>determined with Mesoptometer II</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of contrast threshold level at illumination 0.032 cd/m2 without glare</measure>
    <time_frame>Days 1, 8 and 29</time_frame>
    <description>determined with Mesoptometer II</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recovery time after dazzling</measure>
    <time_frame>Days 1, 8 and 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of potential (µVolt) in retina due to photo activation</measure>
    <time_frame>Baseline, days 1, 8 and 29</time_frame>
    <description>Measured with Standard Electroretinography (ERG)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of subjective efficacy based on a visual analogue scale (VAS) rating questionnaire</measure>
    <time_frame>Pre-dose and days 1, 8 and 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of clinical global impression on a 5-point rating scale</measure>
    <time_frame>Day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with adverse events</measure>
    <time_frame>up to day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with significant changes in laboratory parameters</measure>
    <time_frame>Baseline and day 29</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">195</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Anthocyan capsules</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>capsules containing 160 mg standardised bilberry extract (25% anthocyanidines)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anthocyan capsules</intervention_name>
    <arm_group_label>Anthocyan capsules</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy subjects (volunteers) with age-related impaired twilight and night

          -  Age 50 to 70, men or women

          -  Written informed consent

          -  Full visual acuity (vision ≥ 0.7) according to DIN Standard condition

          -  Refraction ≤ +/-6.0 in the highest main step

          -  Age-related findings in the ophthalmologic examination (anterior chamber and eye
             ground)

          -  Normal intraocular pressure (10-20 mmHg)

        Exclusion Criteria:

          -  Diabetes mellitus

          -  Epilepsy

          -  Abnormal visual acuity or eye ground (e.g. clouding of the lens)

          -  Age related vision problems

          -  Glaucoma and macular degeneration

          -  Disease of the retina

          -  Consumption of anthocyan preparations during the past six months

          -  Opthalmologic pathology: cataract, visus &lt; 0.7, retinal pathology, maculopathy,
             intraocular pressure (&gt; 21 mmHg), known acute or chronic eye disease, use of hard
             contact lenses, eye surgery performed within the last 12 months

          -  Any serious disorder that might interfere with his/her participation in this study and
             the evaluation of the efficacy or safety of the test drug: e.g. diabetes mellitus,
             anamnestic indications of diabetic microangiopathy or polyneuropathy, renal
             insufficiency, hepatic or metabolic dysfunction, cardiovascular disease (hypertension
             &gt; 160/100 mmHg), psychiatric disorder, myasthenia gravis, delirious state, albino

          -  Any treatment that might interfere with the evaluation of the test drug, in particular
             drugs with known influence on eye sight or adaptation (e.g. chloroquine, digitalis,
             ethambutol, chlorpromazine or phenothiazine derivatives such as thioridazine,
             periciazine, perphenazine)

          -  Known hypersensitivity to any of the ingredients of the study drug

          -  Drug and alcohol abuse

          -  Pregnancy, lactation, women of childbearing potential who do not use an established
             contraceptive

          -  Participation in another trial within the past 30 days
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <link>
    <url>http://trials.boehringer-ingelheim.com</url>
  </link>
  <verification_date>July 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 17, 2014</study_first_submitted>
  <study_first_submitted_qc>July 17, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 18, 2014</study_first_posted>
  <last_update_submitted>July 23, 2014</last_update_submitted>
  <last_update_submitted_qc>July 23, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 24, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

